About the project

Integrative structural biology of pathological tau protein, an appealing therapeutic target for Alzheimer's disease modifying drugs

We are aiming to:

  • establish a strong network of academic-industrial partners with cutting-edge, unique proprietary technologies and knowledge
  • achieve scientific advancement in understanding the pathways of tau in neurodegeneration
  • adopt a unique panel of techniques and considering important interaction partners of pathologic tau
  • foster novel tools for neurodegeneration diagnostics and therapy

Project coordinator: CEITEC MU (Czech Republic)
Project partners: Institute of Neuroimmunology, Slovak Academy of Sciences (Slovak Republic) 
 Latvian Institute of Organic Synthesis (Latvia)  Royal College of Surgeons (Ireland)  University of Pittsburgh (USA)  Oregon State University (USA)  University Health Network (Canada)   National University of Cuyo (Argentina)
Project duration: 66 months (01.01.2020 - 30.06.2025)
Project call: H2020-MSCA-RISE-2019
Total budget: 1 058 000

​This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-  Curie grant agreement no. 873127 – InterTAU.

This website reflects only the author's view and the Research Executive Agency (REA) is not responsible for any use that may be made of the information it contains.